Skip to content
Calculator
Guide

Peptides for acne and rosacea: from LL-37 to omiganan

Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board

A woman applying a facial mask in front of a mirror
Photo by Tima Miroshnichenko on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Your skin makes its own antimicrobial peptides. In rosacea, one of them, LL-37, is overproduced and processed into inflammatory fragments.
  • Omiganan, a synthetic antimicrobial peptide, failed one phase 3 rosacea trial and showed a modest benefit in a second. Drugs@FDA lists no application for it.
  • Lower dermcidin in sweat has been linked to acne, but no trial has tested dermcidin as a treatment.
  • A product that claims to treat acne or rosacea is making a drug claim under FDA's rules, whatever peptide it contains.

The skin's own antimicrobial peptides

Skin defends itself chemically as well as physically. Its cells and sweat contain antimicrobial peptides, short molecules that kill bacteria, fungi and viruses and signal to the immune system. Two matter here. LL-37 is the sole human member of the cathelicidin family (laboratory study) 1. Dermcidin is made specifically by sweat glands and secreted onto the skin surface, where a processed form shows broad antimicrobial activity (laboratory study of human sweat) 2.

These peptides help explain both acne and rosacea, but in opposite ways: in acne, there may be too little of the right defence; in rosacea, too much of the wrong kind.

Rosacea: when LL-37 drives inflammation

A key 2007 study found that people with rosacea had abnormally high cathelicidin in their facial skin, processed into different peptide fragments than in healthy skin linked to excess activity of a skin enzyme, stratum corneum tryptic enzyme (kallikrein 5); injecting those rosacea-type fragments into mouse skin increased inflammation, and mice lacking the gene confirmed its role (human tissue and animal study) 3. A 2011 review describes rosacea as a disorder of innate immunity, an explanation that ties together its many triggers and the benefits of existing treatments (review) 4.

That understanding changed how some existing treatments are explained. Azelaic acid 15% is FDA-approved for the inflammatory papules and pustules of mild to moderate rosacea 5. In a 16-week open-label study of 15% azelaic acid gel, patients showed reduced cathelicidin and kallikrein 5 gene expression in their skin, and azelaic acid directly inhibited the enzyme in cultured skin cells; the authors note the study was too small to link these changes to clinical results (open-label study and laboratory work) 6. These findings give no reason to apply more LL-37 to rosacea skin, where it is already raised 3, and a PubMed search on October 27, 2026 found no trial that has tried it; our LL-37 guide covers the peptide in detail.

Omiganan: the antimicrobial peptide that reached phase 3

Omiganan is a synthetic antimicrobial peptide modelled on indolicidin, a peptide from cattle immune cells, and was once described as the most advanced antimicrobial peptide in clinical development (review) 7. It was first developed to prevent catheter infections; that development ceased in 2009 for lack of efficacy, and a later laboratory study proposed that skin proteases had degraded it (laboratory study) 8. Laboratory work, with an author from its developer Cutanea Life Sciences, also showed it can boost interferon responses in immune cells, as LL-37 does (laboratory study) 1.

Its developer then turned to rosacea. According to the company's phase 3 protocol, a first phase 2 study in 240 adults with papulopustular rosacea showed no statistically significant difference between any omiganan group and vehicle in its main analysis; per-protocol comparisons favoured the 2.5% once-daily gel on lesion counts, while the 2.5% twice-daily gel caused more scaling and peeling than vehicle. A second phase 2 study in 240 adults explored once-daily strengths further. The same protocol cites a reduction in inflammatory acne lesion counts with omiganan in two phase 2 trials 9. Two phase 3 rosacea trials followed, each applying a once-daily gel or vehicle for 12 weeks in adults with severe papulopustular rosacea and at least 30 inflammatory facial lesions, with results posted on ClinicalTrials.gov 10 11:

Omiganan phase 3 trial (rosacea)PatientsChange in inflammatory lesions, omiganan vs vehicleTwo-grade IGA improvement
NCT02576860 (completed 2017)263-19.8 vs -20.9 (P = 0.799)24.6% vs 25.6% (P = 0.858)
NCT02547441 (completed 2018)463-18.1 vs -13.5 (P = 0.043)26.3% vs 16.9% (P = 0.019)

In the first, 263 people with severe papulopustular rosacea improved by almost exactly as much on vehicle gel as on omiganan 10. In the second, with 463 people, omiganan reduced lesions and improved overall severity modestly but significantly more than vehicle 11. The vehicle groups improved substantially in both trials 10 11. Drugs@FDA lists no application for omiganan 12.

Acne: dermcidin and the defence that may be missing

Acne involves a skin bacterium, Cutibacterium acnes, along with oil, clogged pores and inflammation. A 2015 study found that recombinant dermcidin killed bacteria in the laboratory and that its expression in sweat was reduced in patients with acne (human study) 13. Similar reductions in sweat dermcidin had been linked to infections in atopic dermatitis (human study) 14. The acne study's authors suggest that lower dermcidin may let the bacterium multiply 13, but the finding has not produced a treatment: searches of PubMed and ClinicalTrials.gov on October 27, 2026 found no trial of dermcidin as an acne therapy. Not every study fits the pattern either; in people with recurrent staphylococcal skin infections, sweat dermcidin was not impaired (human study) 15.

A 2017 review of anti-acne drugs in early clinical trials noted the need for new agents because of antibiotic resistance and the side effects of current options; omiganan was among the candidates it listed (review) 16.

Omiganan in other skin conditions

Omiganan's later trials in other conditions were mixed. In 80 people with mild to moderate atopic dermatitis, it reduced Staphylococcus abundance and increased microbial diversity on the skin but, as the trial's own title states, did not improve clinical symptoms (randomised trial with an author from Cutanea Life Sciences) 17. In facial seborrhoeic dermatitis, it was safe but did not improve the condition against placebo, while ketoconazole did (randomised trial, also with a Cutanea author) 18. In both trials, omiganan did not improve the disease, and in atopic dermatitis it did so despite changing the skin's bacteria.

Why antimicrobial peptides struggle as skin drugs

Antimicrobial peptides look promising in the laboratory: a review describes very wide killing spectra with resistance rare 7, and all-D omiganan was active against MRSA isolates 8. Turning that into clinical benefit has proved difficult, and the papers above point to three reasons. First, skin is full of enzymes that break peptides down; the analysis of omiganan's failed catheter programme proposed that skin proteases degraded it, and tested a mirror-image, all-D version designed to resist them (laboratory study) 8. Second, killing microbes is not the same as treating a disease: in atopic dermatitis omiganan changed the skin's bacteria without improving symptoms 17. Third, the immune effects of these peptides cut both ways, as rosacea shows 3.

Pexiganan, another antimicrobial peptide, illustrates the same pattern. In two phase 3 trials in 835 patients with mildly infected diabetic foot ulcers, compared with an oral antibiotic, one trial failed to show equivalence while the other and the combined data showed similar clinical improvement (randomised trials) 19. Drugs@FDA lists no application for it either 12. Two of the most advanced antimicrobial peptides, then, each ended with one failed and one partly successful pivotal trial.

Where research is heading

Two directions follow from the work above: protease-resistant designs such as the all-D omiganan, so far tested only in the laboratory 8, and treatments that lower cathelicidin and its processing enzyme in rosacea rather than add to them 6.

What is actually in peptide skincare

The peptides named on serum labels, such as palmitoyl pentapeptide-4 or acetyl hexapeptide-8, are not the antimicrobial peptides discussed here. Our skin and hair hub grades each common cosmetic peptide, and our serum label decoder explains the ingredient names. FDA defines drugs by intended use, including articles intended to treat or prevent disease, and gives cleansers intended to treat acne as an example of products regulated as drugs 20.

Injectable peptides for skin

We found no trial of an injected peptide for acne or rosacea. For LL-37, FDA's compounding safety page lists a possible immunogenicity risk from certain routes and peptide-related impurities, says it may be protumorigenic in some tissues, and notes nonclinical findings suggesting detrimental effects on male reproduction (content current as of April 22, 2026) 21; in rosacea it would add more of the peptide already raised in the skin 3.

Questions to ask a dermatologist

  • Is this acne, rosacea or something else, such as seborrhoeic or perioral dermatitis?
  • Which approved treatments suit my type and severity?
  • Could a product's claim to treat my condition be a medicinal claim it cannot back up?
  • Would any peptide product interact with my current treatment?

The bottom line

Antimicrobial peptides are part of the skin's own defence, and they help explain rosacea, where LL-37 is overproduced and inflammatory, and perhaps acne, where sweat dermcidin is reduced. But turning them into treatments has not worked well: omiganan failed one phase 3 rosacea trial, succeeded modestly in another, and has no FDA application on record. The peptides on skincare labels are different molecules altogether.

Frequently asked questions

Are there peptides that treat acne?

Omiganan reached phase 2 acne trials but has no FDA application on record. Research links lower sweat dermcidin to acne, but no trial has tested dermcidin as a treatment.

Does LL-37 help rosacea?

No trial has tested it. In rosacea, the skin already makes abnormally high cathelicidin and processes it into inflammatory fragments; azelaic acid, an approved treatment, lowered cathelicidin in an open-label study.

What happened to omiganan for rosacea?

It had two phase 3 trials in severe rosacea: one, in 263 people, did no better than vehicle; the other, in 463 people, showed a modest benefit. Drugs@FDA lists no application for it.

Do peptide serums help acne?

The peptides on serum labels are cosmetic ingredients, not the antimicrobial peptides tested in acne trials. A product claiming to treat acne is making a drug claim under FDA's rules.

Why does azelaic acid work for rosacea?

One explanation, from an open-label study, is that it lowers cathelicidin and kallikrein 5 activity in rosacea skin.

Sources

  1. Grievink, H. W., et al. (2020). Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll-Like Receptor Ligands in Human Peripheral Blood Mononuclear Cells. Clin Transl Sci, 13(5), 891-895. PMID: 32314872
  2. Schittek, B., et al. (2001). Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol, 2(12), 1133-7. PMID: 11694882
  3. Yamasaki, K., et al. (2007). Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med, 13(8), 975-80. PMID: 17676051
  4. Yamasaki, K., et al. (2011). Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc, 15(1), 12-5. PMID: 22076322
  5. LEO Pharma. FINACEA Foam (azelaic acid) 15% US prescribing information, section 1. DailyMed version 3, effective December 8, 2020; read October 27, 2026.
  6. Coda, A. B., et al. (2013). Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol, 69(4), 570-7. PMID: 23871720
  7. Melo, M. N., et al. (2006). Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Antiinfect Drug Discov, 1(2), 201-7. PMID: 18221145
  8. Ng, S. M. S., et al. (2017). Preliminary investigations into developing all-D Omiganan for treating Mupirocin-resistant MRSA skin infections. Chem Biol Drug Des, 90(6), 1155-1160. PMID: 28581672
  9. Cutanea Life Sciences (the developer). Protocol CLS001-CO-PR-004, revision 2 (March 31, 2017), sections 5.1-5.2 (prior phase 1 and 2 studies), as posted with NCT02547441 on ClinicalTrials.gov. Read October 27, 2026. Source
  10. ClinicalTrials.gov NCT02576860: phase 3 omiganan topical gel vs vehicle in papulopustular rosacea; 263 enrolled; completed September 5, 2017; posted results; sponsor listed as Maruho Co., Ltd. Read October 27, 2026. Source
  11. ClinicalTrials.gov NCT02547441: phase 3 omiganan topical gel vs vehicle in papulopustular rosacea; 463 enrolled; completed April 13, 2018; posted results; sponsor listed as Maruho Co., Ltd. Read October 27, 2026. Source
  12. U.S. Food and Drug Administration. Drugs@FDA, searched through openFDA for omiganan and pexiganan on October 27, 2026: no application found.
  13. Nakano, T., et al. (2015). Reduced expression of dermcidin, a peptide active against propionibacterium acnes, in sweat of patients with acne vulgaris. Acta Derm Venereol, 95(7), 783-6. PMID: 25673161
  14. Rieg, S., et al. (2005). Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol, 174(12), 8003-10. PMID: 15944307
  15. Rieg, S., et al. (2014). Expression of the sweat-derived innate defence antimicrobial peptide dermcidin is not impaired in Staphylococcus aureus colonization or recurrent skin infections. Clin Exp Dermatol, 39(2), 209-12. PMID: 23782241
  16. Zouboulis, C. C., et al. (2017). Anti-acne drugs in phase 1 and 2 clinical trials. Expert Opin Investig Drugs, 26(7), 813-823. PMID: 28627277
  17. Niemeyer-van der Kolk, T., et al. (2022). Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. J Am Acad Dermatol, 86. PMID: 33010325
  18. Rousel, J., et al. (2023). Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. Int J Mol Sci, 24(18). PMID: 37762625
  19. Lipsky, B. A., et al. (2008). Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis, 47(12), 1537-45. PMID: 18990064
  20. U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). Content current as of September 11, 2024; read October 27, 2026. FDA
  21. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (cathelicidin LL-37 entry). Content current as of April 22, 2026; read October 27, 2026. FDA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead